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By Tracie White O n Christmas Eve, 2002, Bryce Faber was diagnosed with a deadly cancer called neuroblastoma. The 2-year-old's treatment, which, in addition to surgery, included massive amounts of radiation followed by even more massive amounts of antibiotics, no doubt saved his life. But those same mega-doses of antibiotics, while staving off infections in his immunosuppressed body, caused a permanent side effect: deafness.
"All I remember is coming out of treatment not being able to hear anything," said Bryce, now a healthy 14-year-old living in Arizona. "I asked my mom, 'Why have all the people stopped talking?'" He was 90 percent deaf.
"The loss has been devastating," said his father, Bart Faber. "But not as devastating as losing him would have been." Treatment with aminoglycosides, the most commonly used class of antibiotics worldwide, is often a lifesaving necessity. But an estimated 20-60 percent of all patients who receive these antibiotics suffer partial or complete hearing loss. Now, in a study published online Jan. 2 in the Journal of Clinical Investigation, researchers at the School of Medicine report that they have developed a modified version of an aminoglycoside that works effectively in mice without the risk of causing deafness or kidney damage, another common side effect.
The researchers hope to test versions of the modified antibiotic in humans as soon as possible.
"If we can eventually prevent people from going deaf from taking these antibiotics, in my mind, we will have been successful," said Anthony Ricci, PhD, professor of otolaryngology-head and neck surgery and co-senior author of the study. "Our goal is to replace the existing aminoglycosides with ones that aren't toxic."
Four years in the making
It took the scientists four years of research to produce 5 grams of the newly patented antibiotic, N1MS, which is derived from siso-
By Sara Wykes
Researchers at the School of Medicine say they have developed a safe and effective skin patch to deliver a drug that enhances the healing of diabetes-related ulcers. The patch, which they tested in mice, may also serve as a way to prevent ulcer formation.
Among the more than 29 million people in the United States with either type-1 or type-2 diabetes, an estimated 15 percent develop ulcers. The ulcers, sores or open wounds that usually occur on the foot, become a secondary health condition that leads to prolonged disability, high rates of recurrence and increased mortality. Nonhealing wounds related to diabetes are the leading cause of nontraumatic amputations in the country.
What causes these ulcers has been known for several years. In 2009, researchers led by Geoffrey Gurtner, MD, a professor of surgery at Stanford, and a group of scientists at the Albert Einstein College of Medicine published a study pinpointing exactly how diabetes reduces the ability of tissue to form new blood vessels essential for wound healing: High levels of blood sugar compromise the body's ability to grow the new blood vessels. That same study found a potential treatment: deferoxamine, or DFO, a drug already approved by the Food and Drug Administration to treat hemochromatosis, a condition in which too much iron accumulates in the body. DFO can correct the Skin patch could help heal, prevent diabetic ulcers
Silicon Valley entrepreneur and philanthropist Sean Parker announced Dec. 17 that he is donating $24 million to establish an allergy research center at the School of Medicine. The center will build on years of work by Stanford scientists to understand all types of allergies, which affect 30-40 percent of the global population.
Immunologist Kari Nadeau, MD, PhD, will lead the Sean N. Parker Center for Allergy Research at Stanford University. An associate professor of pediatrics, Nadeau will guide the center's efforts to understand the underlying mechanisms of allergies in children and adults and to develop lasting allergy cures.
Nadeau has led the field in developing oral immunotherapy to combat severe food allergies, a treatment in which patients consume tiny but gradually increasing doses of their allergy triggers under a doctor's supervision. The center's researchers will continue to investigate food allergies, as well as to conduct studies of other allergic conditions, such as drug allergies and reactions to environmental allergens. Parker, who co-founded the Internet file-sharing service Napster and served as the first president of Facebook, has a personal interest in the topic because of his own experience with severe food allergies.
"We are excited about the center because there is enormous clinical need for better understanding of and treatment for allergies," said Lloyd Minor, MD, dean of the School of Medicine, in a press release announcing the donation. "For instance, the recent profound increase in the incidence of serious food allergy is fascinating and deeply concerning at the same time. Sean Parker's generous gift will enable Stanford Medicine experts, under Dr. Nadeau's leadership, to collaborate and innovate across academic disciplines for the benefit of millions of people with allergies." "I am thrilled and honored to direct the Sean N. Parker Center for Allergy Research at Stanford University," Nadeau said in the release. "Sean is well-versed in immunology, and has been a fantastic partner to work with. He's an entrepreneur and visionary, and we look forward to using this gift and center as the springboard to improve the lives of those adults with allergies through immunotherapy that goes beyond oral therapy." ISM Napster co-founder gives $24 million to launch allergy research center
By Becky Bach
Researchers have found evidence that Medicare reimbursement reforms can reduce the incidence of easily preventable, hospital-acquired health problems.
The reforms have worked as desired for at least two conditions, according to a study by researchers at the School of Medicine.
"We have a win-win. We have patients who are avoiding adverse events while Medicare saves money," said lead author Risha Gidwani, DrPH, a consulting assistant professor of medicine at Stanford and a health economist at the Veterans Affairs Health Economics Resource Center in Menlo Park.
The findings were published online Dec. 12 in the Journal of General Internal Medicine.
In the past, the Centers for Medicare & Medicaid Services paid hospitals based on the treatment patients received, even if the treatment was needed for an easily preventable condition that the patient acquired in When Heather Keller's twins arrived 14 weeks early, she was not only unprepared for their birth, but also overwhelmed by all the medical issues that followed. Brain cysts. Pneumonia. Infections. The problems started at the top of their heads and ended at their toes, she said.
Doctors and nurses patiently and thoroughly explained each new health problem or symptom, but searches on the Internet for additional and detailed information often left Heather and her husband with more questions -and sometimes pretty confused.
"I would try to make sense of what I had been told, but what I would find would make less sense and was written in medical jargon," said Keller, whose twins are now robust, healthy sixth-graders.
Today, Keller works as parent leader for the Family Centered Care Program at Lucile Packard Children's Hospital Stanford, which is part of Stanford Medicine, helping guide and assist parents whose children are patients. She said she would have found great comfort while her babies were still in the hospital had she had access to the new March of Dimes NICU Family Support Program, which was launched at the hospital last year.
Every year, 1,500 babies are admitted to the neonatal intensive care unit at Lucile Packard Children's Hospital Stanford because they have been born too soon or with a medical condition that requires intensive care. Caring for these babies involves the entire family, said Christopher Dawes, the hospital's president and chief executive officer.
"We work very hard to take care of the whole family and not just the baby," Dawes said in announcing the new partnership with the March of Dimes. "This program increases parents' confidence and gives NICU staff the tools they need to support families and babies."
Through the partnership, families of children in the NICU have access to sensitive and appropriate educational materials in print and online, in both English and Spanish. The program helps parents better understand the often complex issues their babies face and the treatments they will receive. The program also provides NICU nurses and staff with additional support for the many questions families may have about a premature birth.
"When you have a premature baby, you have to learn a whole new language. You are so inundated with terms, it's easy to get mixed up," said Keller. "The March of Dimes website and written materials are a great reference that families can use throughout their journey. It's accurate and written in a language that's easy for families to understand, but is not complicated or condescending."
In addition to the materials, the program offers iPads to NICU families, providing them with easy access to the March of Dimes materials and website without having to leave their babies' bedsides.
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A defect in communication between the two halves of the brain may be responsible for some cases of autism, according to a study by researchers at the School of Medicine.
They came to their conclusions by analyzing what's called the human interactome -a vast network of interacting proteins -and by sequencing genomes and analyzing gene expression patterns in individuals with autism.
The study offers a possible explanation as to why the communication center of the brain, called the corpus callosum, is often abnormally small in people with the condition. Although most research has focused on neurons, this study also implicates the oligodendrocytes in the disorder. Oligodendrocytes coat the signaling arms of a neuron with an insulating substance called myelin, which enables electrical signals to move quickly from one neuron to another.
"This is our first glimpse of autism's underlying biological framework, and it implicates a cell type and region of the brain that have not been extensively studied in this disease," said Michael Snyder, PhD, professor and chair of genetics. "Until now, we've suspected that autism could be the result of defects in the neurons themselves. Now it appears that the oligodendrocytes can contribute to the problem by inhibiting neuronal signaling through poor cellular differentiation and myelination."
Snyder, who is also the Stanford W. Ascherman, MD, FACS, Professor in Genetics, is the senior author of the study, published online Dec. 30 in Molecular Systems Biology. Postdoctoral scholar Jingjing Li, PhD, research assistant Minyi Shi and research associate Zhihai Ma share lead authorship of the study.
Module 13
The researchers didn't directly analyze cellular functions in the corpus callosum. Instead, they layered many different types of previously published information about proteins in the brain -those that physically interact with one another, those that are found in similar regions of the brain and those that work in the same pathway or physical process -with mutations found in people with autism. The overlap led them to a group of 119 proteins involved in how nerve cells communicate.
"This protein interaction module contained genes involved in the development and function of oligodendrocytes in the corpus callosum, which directly supports the idea that autism might be due to poor connectivity between brain hemispheres," Li said.
Specifically, the researchers first took the publicly available data about the human protein interactome, which includes information about more than 69,000 protein interactions. They then used an algorithm to divide the interactome into 817 tightly associated subgroups of proteins. Members of these subgroups, or modules, were much more likely to physically associate with one another than with proteins outside their modules.
The researchers then searched among the 192 modules that contained more than five proteins and identified 85 in which many of the proteins were working together to accomplish specific biological tasks, such as adding a chemical tag to DNA-packaging proteins or tagging proteins in a signaling cascade with phosphate molecules. One module, module 13, included many proteins involved in the process of synaptic transmission -the process by which neurons communicate with one another across gaps between cells.
Finally, they examined all the proteins of the 85 modules for overlap with any of the proteins encoded by 383 previously identified autism-associated genes. Although proteins encoded by autism-associated genes could be found in many of the modules, module 13 stood out. It included significantly more autism-associated proteins than would be expected by happenstance:
Twenty-one percent of the 119 proteins in module 13 had been previously associated with autism.
Sequencing DNA
To confirm their findings, the researchers sequenced the complete genomes of six people with autism and the partial genomes, or exomes, of an additional 19 individuals with the condition. The sequencing revealed 38 genes in module 13 that were significantly mutated. Twenty-eight of these mutations had not been previously associated with autism, and 10 of the 28 had been shown in mice to affect behavioral traits or nervous system function.
The researchers consulted the Allen Human Brain Atlas, a kind of three-dimensional map of gene expression, to determine where the genes for the proteins in module 13 are expressed. Although half the genes are expressed throughout the brain, the other half are more specifically expressed in the corpus callosum. The co-expression of both halves of the module in the corpus callosum was further confirmed using frozen, postmortem brain samples, indicating it's active in that region. Because oligodendrocytes are major cellular constituents of the corpus callosum, this study further implicated the involvement of module 13 in oligodendrocytes' differentiation and myelination.
"These findings tell us that we may have to focus our attention on genes involved in different cell types and brain regions, rather than those that had initially raised the suspicions of autism researchers," Li said.
Exciting advance
Finding a new set of autism-associated genes is an exciting advance in the field of autism research, but it won't necessarily lead immediately to new therapies for people with the condition, said Joachim Hallmayer, MD, an associate professor of psychiatry and behavioral sciences and a co-author of the study.
"Autism is an extremely heterogeneous disease," Hallmayer said. "Many genes have been implicated, but environment also plays a role. This study suggests a possible way to subdivide patients into smaller, more homogenous populations based on which genes are mutated. Some of these may be very easy to treat, based on their mechanism, while others may be much more difficult. For those in this category, it's possible we could one day find a way to train or improve the connection between the brain's hemispheres."
Other Stanford co-authors are assistant professor of psychiatry and behavioral sciences Alexander Urban, PhD; pathology resident Jennifer Ziskin, MD, PhD; DNA sequencing program director Ghia Euskirchen; and life science research assistant Shuchun Zhao.
The research was funded by the National Institutes of Health.
Stanford's Department of Genetics also supported the work. ISM newly identified molecular network in brain implicated in autism A new study finds that oligodendrocytes, cells that coat the signaling arms of neurons with an insulating substance called myelin, could play a role in some forms of autism. This is important because until we know how circuits are causing these conditions -not just which are active later -scientists will never be able to treat them in a targeted way.
"You see things activated in brain images, but you can't tell just by watching what is cause and what is effect," said Etkin, MD, PhD, assistant professor of psychiatry and behavioral sciences. Etkin is co-leader of a new interdisciplinary initiative to understand which brain circuits underlie mental health conditions and then find ways to direct noninvasive treatments to those locations.
"Right now, if a patient with a mental illness goes to see their doctor, they would likely be given a medication that goes all over the brain and body," Etkin said. "While medications can work well, they do so for only a portion of people and often only partially." Medications don't specifically act on the brain circuits critically affected in that illness or individual. Etkin has been working with a technology called transcranial magnetic stimulation, or TMS, to map and remotely stimulate parts of the brain. The device, which looks like a pair of doughnuts on a stick, generates a strong magnetic current that stimulates circuits near the surface of the brain.
TMS is currently used as a way of treating depression and anxiety, but Etkin said the brain regions being targeted are the ones available to TMS, not necessarily the ones most likely underlying a person's condition.
Pairing TMS with another technology that shows which brain regions are active, Etkin and his team can stimulate one part of the brain with TMS and look for a reaction elsewhere. These studies can eventually help map the relationships between brain circuits and identify the circuits that underlie mental health conditions.
The team also is working to improve TMS to make it more useful as a therapy. TMS currently only reaches the surface of the brain and is not very focused. The goal is to improve the technology so that it can reach structures deeper in the brain in a more targeted way. "Right now they are hitting the only accessible target," he said. "The parts we really want to hit for depression, anxiety or PTSD are likely deeper in the brain."
I n p a r a l l e l with the TMS work, Baccus and a team of engineers, radiologists and physiologists have been developing a way of using ultrasound to stimulate the brain. Ultrasound is widely used to image the body. But in recent years scientists have learned that at the right frequency and focus, ultrasound can also stimulate nerves to fire.
Technology of the future
In his lab, Baccus uses ultrasound to stimulate nerve cells of the retina, the light-sensing structure at the back of the eye, as part of an effort to develop a prosthetic retina. He is also teaming up with colleagues to understand how ultrasound might be triggering that stimulation. It appears to compress the nerve cells in a way that could lead to activation, but the connection is far from clear.
Other members of the team are modifying existing ultrasound technology to direct it deep within the brain at a frequency that can stimulate nerves without harming them. If the team is successful, ultrasound could be a more targeted and focused tool than TMS for remotely stimulating circuits that underlie mental health conditions.
Leaders of the team have been working together for about five years, and in 2012 got funding from Bio-X NeuroVentures, which eventually gave rise to the Stanford Neurosciences Institute, to pursue this technology. Baccus said that before merging with Etkin's team, his lab had been focusing on the technology without specific brain diseases in mind. "This merger really gives a target and a focus to the technology," he said. ISM
Amy Adams is the director of interdisciplinary life sciences communications for Stanford University.
scientists seek to map and treat the roots of mental illness amit etkin
Stephen Baccus kurt hiCkmAn
Researchers are working with transcranial magnetic stimulation to map and stimulate parts of the brain.
By Erin Digitale
Global health expert Gary Darmstadt, MD, will join the School of Medicine faculty as a professor of pediatrics. His first day on the job will be Feb. 23.
Darmstadt, a former senior fellow and director of family health in the Global Development Division of the Bill & Melinda Gates Foundation, will help lead the school's efforts to improve the health of women and children around the world.
"It is with great pleasure that we welcome Gary to Stanford," said Hugh O'Brodovich, MD, professor and chair of pediatrics and director of the Child Health Research Institute at Stanford. "His experience in directing programs and research that advance global health care for women and children will be a tremendous asset." O'Brodovich is also the Adalyn Jay Physician-inChief at Lucile Packard Children's Hospital Stanford, a part of Stanford Children's Health.
"Gary will help bring special attention to the global impact of preterm birth, which is now the leading cause of death in children under 5 years of age worldwide," said David Stevenson, MD, the school's senior associate dean for maternal and child health. Darmstadt will be joining the efforts of the March of Dimes Prematurity Research Center at Stanford, Stevenson noted.
Before working at the Gates Foundation, Darmstadt held faculty positions at the University of Washington and at Johns Hopkins, where he was the founding director of the International Center for Advancing Neonatal Health at the Bloomberg School of Public Health. His prior experience also includes working with Save the Children, a nongovernmental organization, to direct the research programs of the first major global initiative that addressed newborn survival in low-resource settings. That program, which was funded by the Gates Foundation, played a significant role in putting newborn health on the international public health agenda. "I'm thrilled to have the opportunity to return to Stanford to join a world-class group of colleagues in a diversity of disciplines across the university to tackle major global health challenges facing women, childrenDarmstadt completed a residency in dermatology at Stanford in 1995. Already trained as a pediatrician at Johns Hopkins when he arrived, he studied how infectious disease manifested in the skin, and how dermatologic signs of disease could provide insights into health status and give clues to new interventions to improve the survival, health and development of children in impoverished parts of the world. That research helped to catalyze his broader interests in promoting health in developing countries, he said.
"Gary has made a significant impact on neonatal health worldwide, particularly by championing the use of chlorhexidine for umbilical cord cleansing, and by developing community-based guidelines for the essentials of newborn care," said Michele Barry, MD, professor of medicine and director of Stanford's Center for Innovation in Global Health. "We are so glad to have him join us."
In his new role, Darmstadt will collaborate with several other Stanford experts in international medicine, including Barry and Yvonne Maldonado, MD, professor of pediatrics and of health research and policy. He plans to study how to reduce gender inequality in developing countries in order to improve community health. Darmstadt will also examine ways of ensuring healthy birth, growth and development of children in these countries. "As child survival rates improve, we need to focus more on optimizing the neurodevelopment and productivity of children so that they have opportunities to grow up and make contributions that will help bring their countries out of poverty," he said.
Within the Department of Pediatrics, Darmstadt will work in the Division of Neonatal and Developmental Medicine and the Division of Infectious Diseases. He also will be an associate dean for maternal and child health, reporting to Stevenson, and will co-direct the Department of Pediatrics' Global Health Initiative. ISM expert in global health will join school of medicine faculty Gary darmstadt "Gary will help bring special attention to the global impact of preterm birth.
By Bjorn Carey
Landing an airplane is one of the most difficult piloting techniques to master, and the stats show it: 36 percent of all airplane accidents and 25 percent of fatalities occur during the final approach and landing.
New research by scientists at the School of Medicine and the VA Palo Alto Health Care System reveals that expert pilots make better decisions during this phase than less experienced pilots because their brains behave more efficiently.
The study, published Nov. 26 in PLOS ONE, could lead to technology and techniques that guide pilots to more efficient brain behaviors in order to improve flight safety.
The researchers rigged a fMRI machine so that 20 pilots -12 moderately experienced pilots and eight experienced pilots -could operate the controls of a flight simulator while having their brain activity scanned in real time. The simulator mimicked the cockpit of a singleengine airplane, and the pilots were instructed to land at a virtual San Francisco International Airport.
The trial started the pilots at 350 feet of altitude. They were instructed to begin their descent based only on their instrument readings, as would be typical in most real-life flights. Once they reached 200 feet -the altitude at which the Federal Aviation Administration mandates you must be able to clearly see the runway in order to land -the program would display the runway, either clearly or obscured by varying degrees of fog.
The pilots would then need to flash their gaze from the instruments to the runway and back to make a snap decision about whether or not it would be safe to continue the approach.
Better decisions, half the brain activity
After multiple attempts per pilot, the results showed that the expert pilots made the correct decision about whether to make a landing attempt or abort 80 percent of the time, whereas the moderately experienced pilots did so only 64 percent of the time. Interestingly, the fMRI scans revealed that the expert pilots scored higher while displaying only half as much brain activity.
Landing a plane involves constantly This is an area of the brain involved in regulating gaze as the eyes quickly shift their focus to different fixed objects. The work needs to be replicated to confirm the caudate nucleus' role in instrument scanning, Adamson added.
Other brain structures or mechanisms might be playing a role in visual processing for pilots. But this work opens the door to pairing fMRI and flight simulators -something that NASA is already doing in limited trials -to test pilots' mental engagement during various flight maneuvers. Researchers might also be able to design interactive lessons that guide less expert pilots into behaviors that mimic the more efficient brain activity of more expert pilots.
Other implications "In the future, we could put a trainee in a scanner and see what mechanism in their brain they're using to get better at the task, and train them to reallocate resources in the brain more efficiently," Adamson said. "If we are able to train pilots to process instruments and other visual cues more efficiently, you could reduce the likelihood of accidents during landing."
Although these findings were obtained by testing aircraft pilots, they may also have implications for skilled task performance and aging in general. Prior work in the same laboratory showed how slower speed of information processing predicts worse performance on aviationrelated tasks in older pilots. The current research offers an insight into how more efficient brain activity and information processing may provide a countermeasure to loss of speed of processing with aging. Researchers rigged a fMRi machine so that 20 pilots -12 moderately experienced pilots and eight experienced pilotscould operate the controls of a flight simulator while having their brain activity scanned in real time. The flight simulator depicted either a relatively clear view of the runway (top) or conditions that made it too foggy to land (bottom).
By Krista Conger
Like human patients, mice with a form of Duchenne muscular dystrophy undergo progressive muscle degeneration and accumulate connective tissue as they age. Now, researchers at the School of Medicine have found that the fault may lie at least partly in the stem cells that surround the muscle fibers.
They've found that during the course of the disease, the stem cells become less able to make new muscle and instead begin to express genes involved in the formation of connective tissue. Excess connective tissue -a condition called fibrosis -can accumulate in many organs, including the lungs, liver and heart, in many different disorders. In the skeletal muscles of people with muscular dystrophy, the fibrotic tissue impairs the function of the muscle fibers and leads to increasing weakness and stiffness, which are hallmarks of the disease.
The researchers discovered that this abnormal change in stem cells could be inhibited in laboratory mice by giving the animals a drug that is already approved for use in humans. The drug works by blocking a signaling pathway involved in the development of fibrosis. Although much more research is needed, the scientists are hopeful that a similar approach may one day work in children with muscular dystrophy. "These cells are losing their ability to produce muscle, and are beginning to look more like fibroblasts, which secrete connective tissue," said Thomas Rando, MD, PhD, professor of neurology and neurological sciences. "It's possible that if we could prevent this transition in the muscle stem cells, we could slow or ameliorate the fibrosis seen in muscular dystrophy in humans." A paper describing the researchers' findings was published Dec. 17 in Science Translational Medicine. Rando, the paper's senior author, is director of the Glenn Laboratories for the Biology of Aging and founding director of the Muscular Dystrophy Association Clinic at Stanford. Former postdoctoral scholar Stefano Biressi, PhD, is the lead author. Biressi is now at the Centre for Integrative Biology at the University of Trento in Italy.
A devastating disease
Duchenne muscular dystrophy is a devastating disease that affects about 1 in every 3,600 boys born in the United States. Patients usually experience severe, progressive muscle weakness that confines them to a wheelchair in early adolescence and eventually leads to paralysis. It's caused by mutations in the dystrophin gene, which encodes the dystrophin protein. The dystrophin protein serves to connect muscle fibers to the surrounding external matrix. This connection stabilizes the fibers, enhancing their strength and preventing injury. Sufferers are nearly always boys because the dystrophin gene is located on the X chromosome. (Girls would need to inherit two faulty copies, which is unlikely because male carriers often die in early adulthood.)
Under normal conditions, muscle stem cells respond to muscle damage by dividing into two daugter cells, one of which becomes new muscle, while the other remains a stem cell. However, in the mice missing the dystrophin gene, the muscle stem cells slowly assume a different fate. They begin to resemble fibroblasts instead of muscle-making machines.
To conduct the research, By Bruce Goldman
The mass die-off of nerve cells in the brains of people with Alzheimer's disease may largely occur because an entirely different class of brain cells, called microglia, begin to fall down on the job, according to a new study by researchers at the School of Medicine.
The researchers found that, in mice, blocking the action of a single molecule on the surface of microglia restored the cells' ability to get the job done -and reversed memory loss and myriad other Alzheimer's-like features in the animals.
The study, published online Dec. 8 in The Journal of Clinical Investigation, illustrates the importance of microglia and could lead to new ways of warding off the onset of Alzheimer's disease, which is predicted to afflict 15 million people by mid-century unless some form of cure or prevention is found. The study also may help explain an intriguing association between aspirin and reduced rates of Alzheimer's.
Microglia, which constitute about 10-15 percent of all the cells in the brain, actually resemble immune cells considerably more than they do nerve cells.
"Microglia are the brain's beat cops," said Katrin Andreasson, MD, professor of neurology and neurological sciences and the study's senior author. "Our experiments show that keeping them on the right track counters memory loss and preserves healthy brain physiology."
Implicated: a single molecule
A microglial cell serves as a frontline sentry, monitoring its surroundings for suspicious activities and materials by probing its local environment. If it spots trouble, it releases substances that recruit other microglia to the scene, said Andreasson. Microglia are tough cops, protecting the brain against invading bacteria and viruses by gobbling them up. They are adept at calming things down, too, clamping down on inflammation if it gets out of hand. They also work as garbage collectors, chewing up dead cells and molecular debris strewn among living cells -including clusters of a protein called A-beta, notorious for aggregating into gummy deposits called Alzheimer's plaques, the disease's hallmark anatomical feature.
A-beta, produced throughout the body, is as natural as it is ubiquitous. But when it clumps into soluble clusters consisting of a few molecules, it's highly toxic to nerve cells. These clusters are believed to play a substantial role in causing Alzheimer's.
"The microglia are supposed to be, from the get-go, constantly clearing Abeta, as well as keeping a lid on inflammation," Andreasson said. "If they lose their ability to function, things get out of control. A-beta builds up in the brain, inducing toxic inflammation."
The Stanford study provides strong evidence that this deterioration in microglial function is driven, in large part, by the heightened signaling activity of a single molecule that sits on the surface of microglial and nerve cells. Previous work in Andreasson's lab and other labs has shown that this molecule, a receptor protein called EP2, has a strong potential to cause inflammation when activated by binding to a substance called prostaglandin E2, or PGE2.
"We'd previously observed that if we bioengineered mice so their brain cells lacked this receptor, there was a huge reduction in inflammatory activity in the brain," she said. But they didn't know whether nerve cells or microglia were responsible for that inflammatory activity, or what its precise consequences were. So they determined to find out.
Preserving memory
The experiments began in a dish. Isolating viable microglia from the brain is quite difficult. But it's easy to harvest large numbers of their close cousins, immune cells called macrophages. These cells circulate throughout the body and can be readily obtained from a blood sample. While not carbon copies of one another, microglia and macrophages share numerous genetic, biochemical and behavioral features.
When placed in a dish with soluble A-beta clusters, macrophages drawn from young mice responded calmly, producing recruiting chemicals and not ramping up production of inflammatory molecules. Notably, the output of A-beta-chewing enzymes in these young cells was robust. But macrophages from older mice acted differently: A-beta's presence incited a big increase in EP2 activity in these cells, resulting in amped-up output of inflammatory molecules and reduced generation of recruiting chemicals and A-beta-digesting enzymes.
This early hint that agerelated changes in EP2 action in microglia might be promoting some of the neuropathological features implicated in Alzheimer's was borne out in subsequent experiments for which Andreasson's team used mice genetically predisposed to get the mouse equivalent of Alzheimer's, as well as otherwise normal mice into whose brains the scientists injected either A-beta or a control solution. In both groups of mice, the expected deleterious effects on memory and learning didn't arise if EP2 within microglial cells was absent, as a result of a genetic manipulation. Blocking microglial EP2 activity significantly improved these animals' performance on two kinds of standard memory tests: one that assesses how quickly a mouse forgets that it has encountered an object before, and another that rates the mouse's ability to remember where a food reward is in a maze.
Looking beyond aspirin
Clearly, knocking out EP2 action in A-beta-provoked microglia benefited memory in mice that had either gradually (the "Alzheimer's" mice) or suddenly (the brain-injected mice) acquired excessive A-beta in their brains. Likewise, mouse microglia bioengineered to lack EP2 vastly outperformed unaltered microglia, in A-beta-challenged brains, at such critical tasks as secreting recruiting chemicals and factors beneficial to nerve cells and in producing inflammationcountering, rather than inflammationspurring, proteins.
Epidemiological reports suggest that the use of nonsteroidal anti-inflammatory drugs, such as aspirin, can prevent the onset of Alzheimer's -although only if their use is initiated well before any signs of the disorder begin to show up in older people, Andreasson said. "Once you have any whiff of memory loss, these drugs have no effect," she said. NSAIDs' mainly act by blocking two enzymes called COX-1 and COX-2; these enzymes create a molecule that can be converted to several different substances, including PGE2 -the hormone-like chemical that triggers EP2 action.
Although PGE2 is known to regulate inflammatory changes in the brain, it exercises diverse, useful functions in different tissues throughout the body, from influencing blood pressure to inducing labor. Complicating matters, PGE2 is just one of five different prostaglandins originating from the precursor molecule produced by COX-1 and COX-2. So aspirin and other COX-1-and COX-2-inhibiting drugs may have myriad effects, not all of them beneficial. It may turn out that a compound blocking only EP2 activity on microglial cells, or some downstream consequences within microglial cells, would be better-suited for fending off Alzheimer's without side effects, said Andreasson. Meanwhile, her group is exploring the biological mechanisms via which PE2 signaling pushes microglia over to the dark side.
Former Stanford postdoctoral scholar Jenny Johansson, PhD, is the lead author of the study. Other Stanford co-authors are former graduate student Nathan Woodling, PhD; postdoctoral scholars Siddhita Mhartre, PhD, and Holden Brown, PhD; research associate Xibin Liang, MD, PhD; life-science research assistants Qian Wang and Maharshi Panchal; and undergraduate Taylor Loui.
The study was supported by the National Institutes of Health, the Alzheimer's Association, the Swedish Research Council and the National Science Foundation.
Stanford's Department of Neurology and Neurological Sciences also supported the work. ISM blocking receptor in immune cells counters 'Alzheimer's' in mice Katrin Andreasson is senior author of a study that implicates malfunction in the brain's immune cells in Alzheimer's disease.
steve fisCh
Biressi and Rando used a strain of laboratory mice in which the muscle stem cells were engineered to glow with a fluorescent light when treated with a drug called tamoxifen. They then bred the mice with another strain in which the dystrophin gene is mutated, and followed the fate of the cells over time.
The researchers found that the expression of myogenic genes, which are associated with the regeneration of muscle in response to injury, was nearly completely lacking in many of the muscle stem cells in the mice after just 11 months, while the expression of fibrotic genes had increased compared with that of control animals. The cells from the dystrophic animals were also oddly located: Rather than being nestled next to the muscle fibers, they had begun to move away into the spaces between tissues.
The role of a signaling pathway
Rando and Biressi knew that a similar, but much less pronounced, accumulation of connective tissue in muscle fibers occurs during normal aging. That process is governed by signaling proteins, which include the Wnt and TGF-beta protein families. Wnt plays a critical role in embryonic development and cancer; TGF-beta controls cell division and specialization. They wondered whether blocking the Wnt/TGF-beta pathway in the dystrophic mice would inhibit fibrosis in the animals' muscles.
The researchers turned to a drug called losartan, which is used to treat high blood pressure. Losartan inhibits the expression of the genes for TGF-beta types 1 and 2. The researchers thought it would probably interrupt the signaling pathway that leads the muscle stem cells astray.
Treating the mice with losartan, they found, did in fact prevent the muscle stem cells from expressing fibrosis-associated genes and partially maintained their ability to form new muscle.
"This scar tissue, or fibrosis, leaves the muscle less elastic and impairs muscle function," Rando said. "So we'd like to understand why it happens, and how to prevent it. It's also important to limit fibrosis to increase the likelihood of success with other possible therapies, such as cell therapy or gene therapy."
Next steps
Because TGF-beta type 1 plays many roles throughout the body, the researchers are now working to find ways to specifically inhibit TGF-beta type 2, which is involved in the transition of the muscle stem cells. They're also interested in learning how to translate the research to other diseases.
"Fibrosis seems to occur in a vicious cycle," Rando said. "As the muscle stem cells become less able to regenerate new muscle, the tissue is less able to repair itself after damage. This leads to fibrosis, which then further impairs muscle formation. Understanding the biological basis of fibrosis could have a profound effect on many other diseases."
Other Stanford researchers include visiting scholar Elen Miyabara, PhD, from the University of São Paulo in Brazil; postdoctoral scholar Suchitra Gopinath, PhD; and research assistant Poppy Carlig.
The research was funded by the National Institutes of Health, the Department of Veterans Affairs, the Muscular Dystrophy Association and the Coordenação de Aperfeiçoamento de Pessoal de Nivel Superior.
Stanford's Department of Neurology and Neurological Sciences also supported the work. ISM 
Clots and blockages
Gidwani selected two of these conditions: pulmonary embolism, a blockage of an artery that supplies the lung; and deep-vein thrombosis, a blood clot that forms in a vein that can cause pulmonary embolism. Patients who receive hip or knee replacements are likely to develop these conditions without proper care, which usually consists of ambulation, mechanically-assisted movement or medication.
She examined records from 2007 to 2009 from a national database of American hospital discharges, comparing Medicare patients ages 65-69 who received a hip or knee replacement with non-Medicare patients ages 60-64 who received the same procedures.
When CMS stopped paying for treating deep-vein thromboses and pulmonary embolisms, the incidence of those conditions after hip or knee replacement surgery dropped 35 percent in the Medicare population, Gidwani said.
In the younger, non-Medicare population, the incidence of these two conditions increased, although they also decreased in the patients over age 65 who had private insurers. There are more than 1 million hip or knee replacements performed in the United States each year, and over 60 percent of them are paid for by Medicare.
Gidwani ran statistical analyses to ensure the results were not due to differences in the length of hospital stay or potential differences in billing practices among the hospitals.
Getting results
"This study provides evidence the reimbursement reform had the desired effect," Gidwani said. "This is important information if Medicare or private payers are thinking about expanding value-based purchasing programs."
The co-author is Jay Bhattacharya, MD, PhD, professor of medicine and director of the Stanford Program on Medical Outcomes.
"It may seem obvious that Medicare should use payment incentives for providers to encourage better and more appropriate care for patients, but there is always a risk of unintended consequences when Medicare cuts payments for services," Bhattacharya said. "In this case, we have found evidence that Medicare's refusal to pay for complications arising from hip and knee surgeries really did reduce the incidence of those complications. I believe that there may be many more opportunities to improve patient outcomes by reforming provider payment practices, though lots of careful research will be needed to identify them."
Stanford's Department of Medicine helped to support the study, for which there was no outside funding.
ISM

Lisa Marie Potter is a science-writing intern for the medical school's Office of Communication & Public Affairs.
diabetes-impaired expression of a protein that supports new vascular growth.
The problem was how to deliver the DFO, which would be toxic if used for as long as diabetic pressure ulcers can take to heal. So the researchers decided to investigate an alternative: local delivery of just enough medication directly to an ulcer through a patch applied to the skin. Dominik Duscher, MD, a postdoctoral scholar in surgery, and Evgenios Neofytou, MD, an instructor at the Stanford Cardiovascular Institute, share lead authorship of a paper describing the findings of the new research. Gurtner is the senior author. The paper was published online Dec. 22 in the Proceedings of the National Academy of Sciences.
Challenges of developing a patch
Developing the skin patch raised a set of formidable challenges, which the Stanford team took on, step by step, working with materials engineers led by co-author Jayakumar Rajadas, PhD, director of Stanford's Biomaterials and Advanced Drug Delivery Laboratory.
The DFO needed to be modified to penetrate the outermost layer of the skin to activate the formation of new blood vessels, but its release also needed to be controlled to prolong the availability of the DFO at a therapeutic level. It took nearly four years of attempts before the team produced a solution: Envelope the DFO with a surfactant, which would lower the DFO's natural surface tension and transform its molecules into microparticles that could penetrate the skin, then embed them in a pliable polymer matrix, a couple of millimeters thick, that would protect the fragile DFO microparticles and disperse them gradually as the matrix disintegrated.
"The mice tolerated it very well," Duscher said, which could bode well for humans. Once the patch is applied -the moisture in skin makes a natural adherent -the diffusion of the DFO begins and its molecules are drawn into the wounded tissue and skin.
'Hope to start clinical trials soon'
Not only did the wounds in the mice heal more quickly, Duscher said, but the quality of the new skin was even better than the original. The researchers also used the DFO matrix on a mouse with diabetes to see if it would prevent ulcer formation -and it did. "We were very excited by the results," Duscher said, "and we hope to start clinical trials soon to test this in humans." "This same technology is also effective in preventing pressure ulcers, which are a major source of morbidity and mortality in patients with neurologic injury or the elderly," said Gurtner, who is also the Johnson & Johnson Distinguished Professor in Surgery II. "The actor Christopher Reeve actually died from a pressure ulcer and not his spinal cord injury, which really emphasizes the extremely limited therapeutic options for these patients."
Other Geoffrey Gurtner and his colleagues have developed a skin patch to deliver a drug that could enhance the healing of diabetes-related ulcers and prevent their development.
Lecture series established by dean kicks off Jan. 23; intial talks to focus on diversity Lloyd Minor, MD, dean of the School of Medicine, has established the Dean's Lecture Series to bring leading innovators from a variety of fields to Stanford.
Initially, the series will focus on diversity, kicking off Jan. 23 with a presentation by Rosalind Hudnell, the chief diversity officer at Intel Corp.
"We all benefit from the transformative power of diversity," Minor said. "It is an integral part of what it means to lead the biomedical revolution and a core value of the Stanford Medicine community."
Minor said he launched the lecture series to unite students, faculty and staff and to spark dialogue on issues of importance. "This lecture series will support Stanford Medicine's culture of learning, as well as fuel personal and professional growth," he said.
The following lectures have been scheduled:
• Jan. 23: Hudnell, chief diversity officer and global director of education and external relations at Intel.
• Feb. 20: Vivek Wadhwa, fellow at the Center for Corporate Governance at Stanford.
• May 1: Ruth Simmons, president emerita of Brown University.
All lectures will be held from noon to 1 p.m. in Berg Hall at the Li Ka Shing Center for Learning and Knowledge.
For more information on the lecture series, visit http://med.stanford.edu/deanslectures. ISM Stanford Sleep center recognized for expertise in treating restless legs syndrome
The Stanford Center for Sleep Sciences and Medicine was named a quality care center by the WillisEkbom Disease Foundation.
It is the fifth center or clinic worldwide to be recognized for its expertise on Willis-Ekbom Disease, which is also known as restless legs syndrome. Four of Stanford's sleep specialists have expertise in treating restless legs syndrome, a chronic neurological disorder that can interrupt sleep and reduce the quality of life.
"Our partnership with the WED Foundation will improve the quality of life for individuals with Willis-Ekbom disease by guaranteeing the highest standard of care," said restless legs syndrome specialist Juliane Winkelmann, MD, professor of neurology and neurological sciences at Stanford.
ISM
Pulmonary hypertension program accredited as comprehensive care center
The Stanford Adult Pulmonary Hypertension Program is one of only seven programs nationwide to have been accredited as a comprehensive care center by the Pulmonary Hypertension Association.
"We're very excited to be one of the first centers in the country to get this accreditation," said Juliana Liu, a nurse practitioner in the Vera Moulton Wall Center for Pulmonary Vascular Disease. "It's really a recognition for the work we've been trying to do for many years."
Pulmonary hypertension, high blood pressure in the arteries and capillaries of the lungs, can lead to rightheart failure. Its causes may include genetic, environmental and immunological factors. Stanford earned the accreditation by demonstrating its ability to care for a broad spectrum of patients, Liu said. The center also conducts research. "The reviewers said Stanford is the model that programs across the country should emulate," Liu said. ISM 7 micin, a type of aminoglycoside.
N1MS cured urinary tract infection in mice just as well as parent compound, but did not cause deafness, study results show. The study presents a promising new approach to generating a new class of novel, nontoxic antibiotics, Ricci said.
The two senior authors -Ricci and Alan Cheng, MD, associate professor of otolaryngology-head and neck surgery -joined forces in 2007 to explore the idea of creating new and improved versions of aminoglycosides based on a simple yet groundbreaking idea born of Ricci's basic science research into the biophysics of how hearing works within the inner ear. "It's a nice example of how basic science research is directly translatable into clinical applications," said Ricci.
Ricci is an expert on the process by which sound waves open ion channels within the sensory hair cells of the inner ear, allowing their conversion to electrical signals that eventually reach the brain.
Because aminoglycosides cause deafness by killing these nonregenerating hair cells, Ricci postulated, why not simply make the drug molecules unable to enter the cells' channels?
The idea made sense to Cheng. "As a clinician-scientist, I treat kids with hearing loss," Cheng said. "When a drug causes hearing loss, it is devastating, and it's especially disturbing when this happens to a young child as they rely on hearing to acquire speech.
"When I came to Stanford seven years ago from the University of Washington, I was exploring the angle that maybe we could add drugs to protect the ear from toxicity. Tony brought up this new idea: Why don't we just not let the drug get in? Great idea, I thought. When do we start to work?"
A potent antibiotic
For 20 years, and despite newer, alternative antibiotics, aminoglycosides have remained the mainstay treatment worldwide for many bacterial diseases, including pneumonia, peritonitis and sepsis. They also are often used when other antibiotics have failed to treat infections of unknown origins.
Their popularity is due, in part, to their low cost, lack of need for refrigeration and effectiveness at treating bacterial infections at a time when the declining potency of antibiotics is a major public health concern. They are frequently used in neonatal intensive care units to battle infections, or even the threat of infections, which pose a mortal risk for babies. Exactly how many premature babies suffer hearing loss as a side effect of treatment with the drug is unknown, Ricci said.
"The toxicity of these drugs is something we accept as a necessary evil," said Daria MochlyRosen, PhD, director of SPARK, a program at Stanford that assists scientists in moving their discoveries from bench to bedside.
SPARK worked closely with Ricci and Cheng, providing both the funding and the expertise necessary as they entered the new landscape of drug development. "Being an expert on the inner ear put Dr. Ricci in a unique position to help design a better drug -one that would be a huge advantage, especially for premature babies," Mochly-Rosen said. "This is a project that could make a huge difference in human health."
For decades, researchers have looked for ways of preventing aminoglycosides from killing off the hearing cells of the inner ear, Ricci said.
"So many approaches have failed," Ricci said. "The main problem has been that if you succeeded in stopping the drug from killing hair cells, then you also stopped its antimicrobial effect. The drug just doesn't work anymore."
The goal, Ricci said, was to keep the antibacterial properties of the drug intact while preventing it from entering the inner-ear cell's ion channels. He and his fellow researchers used data from structural biologists at Stanford who better understood how the antibiotics fought off infection.
"We figured, well, let's not mess with that part of the drug," Ricci said. "We targeted sites on the drug molecule that were not involved in the antimicrobial activity that kills off infection. This allowed us to reduce toxicity to the ear while retaining antimicrobial action."
The researchers made nine different compounds derived from sisomicin. All nine were significantly less toxic than sisomicin to hair cells when tested in the laboratory. Three of the nine were comparable to sisomicin in inhibiting the growth of and killing E. coli bacteria. Of the three derivatives, however, N1MS was the most effective against the bacteria, and the researchers used it to successfully treat E. coli-caused bladder infection in a mouse model while leaving hearing intact. They also found that, unlike the parent compound, N1MS was nontoxic to the kidneys.
"We postulate that entry into kidney cells is also through a channel, and so entry is reduced here as well," Ricci said. "It is speculation at this point because unlike with the hair cell, we have not measured drug entry into the kidney cells, but it seems reasonable."
Other Stanford co-authors are postdoctoral scholars Markus Huth, MD, Yi-Ju Hsieh, PhD, Thomas Effertz, PhD, Kyu-Hee Han, MD, and Sarah Verhoeven, MD; research assistants Kayvon Sotoudeh and Andrew Vu, MD; Michael Hsieh, MD, PhD, assistant professor of urology; and SPARK chemistry consultant Robert Greenhouse, PhD.
The study was funded by the National Institutes of Health, the Swiss National Science Foundation, the Jerry Yang Faculty Scholar Fund and SPARK.
Stanford's Department of Otolaryngology-Head and Neck Surgery also supported the work.
For information on Stanford's Hearing Loss Initiative, visit: https://hearinglosscure.stanford.edu. ISM Antibiotic continued from page 1 "When a drug causes hearing loss, it is devastating."
By Bruce Goldman
A study of more than 9,000 men with fertility problems has revealed a correlation between the number of different defects in a man's semen and the likelihood that the man has other health problems.
The study, conducted by investigators at the School of Medicine, also links poor semen quality to a higher chance of having various specific health conditions, such as hypertension, and more generally to skin and endocrine disorders.
The findings, published online Dec. 10 in Fertility and Sterility, may spur more-comprehensive approaches to treating male infertility. They also point to the wisdom of performing complete physical examinations of men experiencing reproductive difficulties.
"About 15 percent of all couples have fertility issues, and in half of those cases the male partner has semen deficiencies," said the study's lead author, Michael Eisenberg, MD, assistant professor of urology and director of male reproductive medicine and surgery at Stanford. "We should be paying more attention to these millions of men. Infertility is a warning: Problems with reproduction may mean problems with overall health."
A study Eisenberg co-authored a few years ago showed that infertile men had higher rates of overall mortality, as well as mortality linked to heart problems, in the years following an infertility evaluation. "But here, we're already spotting signs of trouble in young men in their 30s," he said. 50 years old, who had been evaluated at Stanford Hospital & Clinics (now Stanford Health Care) between 1994 and 2011 to determine the cause of their infertility. The men had routinely provided semen samples, which the researchers assessed for characteristics including volume, concentration and motility. In about half of all the male infertility cases, the problem was abnormal semen; in the rest, the fault lay elsewhere. So, using the database, the investigators were able to compare the overall health status of men who had semen defects to that of the men who didn't.
With a median age of 38, this was a fairly young group of men. However, 44 percent of all the men had some additional health problem besides the fertility problem that brought them to the clinic. In particular, the investigators found a substantial link between poor semen quality and specific diseases of the circulatory system, notably hypertension, vascular disease and heart disease. "To the best of my knowledge, there's never been a study showing this association before," said Eisenberg. "There are a lot of men who have hypertension, so understanding that correlation is of huge interest to us."
In addition, as the number of different kinds of defects in a man's semen rose, so did his likelihood of having a skin disease or endocrine disorder. When looking at the severity of all health problems, the scientists observed a statistically significant connection between the number of different ways in which a man's semen was deficient and the likelihood of his having a substantial health problem.
Health, semen quality correlated
The study wasn't designed to determine precisely how connections between semen deficiencies and seemingly unrelated disorders, such as cardiovascular or endocrine disease, come about. But, Eisenberg noted, some 15 percent of all genes in the human genome are connected fairly directly to reproduction, and most of these genes also have diverse functions in other bodily systems. He also noted that it may not be a disease itself, but the treatment for the disease, that's actually responsible for reproductive malfunction. He said he is exploring this possibility now.
"A man's health is strongly correlated with his semen quality," he said. "Given the high incidence of infertility, we need to take a broader view. As we treat men's infertility, we should also assess their overall health. That visit to a fertility clinic represents a big opportunity to improve their treatment for other conditions, which we now suspect could actually help resolve the infertility they came in for in the first place."
The senior author of the study is Mark Cullen, MD, professor of medicine at Stanford. Other Stanford coauthors are professor of reproductive endocrinology and fertility Barry Behr, PhD; former professor of obstetrics and gynecology Renee Reijo Pera, PhD; and statistical programmer Shufeng Li.
The study was supported in part by the To request an appointment, call or you can make an appointment online. disorders. He also investigates the role of sex chromosomes and hormones in brain development.
P L E A S E G I v E B L O O D
RoBIN KaMaL, MD, was appointed assistant professor of orthopedic surgery, effective Oct. 1. He treats hand, wrist and elbow disorders. His research concentrates on assessing and maintaining quality in hand surgery, and on studying wrist kinematics to improve wrist reconstruction.
LeI StaNLey QI, PhD, was appointed assistant professor of bioengineering, effective Oct. 1. He develops techniques to edit and regulate animal genomes, and studies the genetics and epigenetics of cell proliferation, differentiation and complex disease.
eRIN tURK, a graduate student, won a Genetics Society of America poster award for her work, "A new member of the tubulin superfamily orients cilia in multiciliated epithelial cells," at the 15 th International Xenopus Conference in August. Turk is a member of the lab of Tim Stearns, PhD, professor of biology and of genetics. She studies zeta-tubulin, a protein found in frogs that helps orient cilia to ensure the fluid in tissues moves in a single direction.
KeIth VaN haReN, MD, was appointed assistant professor of neurology and neurological sciences, effective Nov. 1. He treats adults and children with a range of genetic disorders or autoimmune brain disorders. He is developing therapies and care strategies for patients with neurodegenerative disorders, particularly those affecting myelin.
Ke yUaN, PhD, a postdoctoral scholar, received the Cournand and Comroe Young Investigator Award from the American Heart Association for her work on pulmonary hypertension. The award honors the accomplishments of early career investigators. She examines signaling in endothelial and pericyte cells. She is working to understand the molecular mechanisms that regulate pulmonary hypertension. ISM aNNe BRUNet, PhD, was promoted to professor of genetics, effective Nov. 1. She studies the genetic and epigenetic mechanisms that regulate aging and rejuvenation. Her team is also developing a new model system, the African killifish, to understand vertebrate aging and to examine the evolution of life span differences.
KaRL deISSeRoth, MD, PhD, was named the 2014 Scientist of the Year by R&D Magazine. He led the development of optogenetics, the integration of genetics and optics to allow for the control of cells within intact biological systems. He also led the development of CLARITY, a method of creating transparent biological models using a tissue-hydrogel hybrid. Using optogenetics and CLARITY, he investigates Parkinson's disease, anxiety, social dysfunction, depression and other psychiatric disorders.
haRRy GReeNBeRG, MD, professor of medicine and of microbiology and immunology, was voted chair-elect of the American Association of the Advancement of Science Section on Medical Sciences. He directs Spectrum, the Stanford Center for Clinical and Translational Science, and is the medical school's senior associate dean for research. He studies influenza and rotavirus infections, with a focus on microbial pathogenesis and innate and acquired immunity.
MIchaeL GReIcIUS, MD, MPH, was promoted to associate professor of neurology and neurological sciences, effective Nov. 1. He recently received a $300,000 McKnight Foundation Memory and Cognitive Disorders Award. He uses brain imaging, biomarkers and genetics to understand the role of a gene variant in Alzheimer's disease. He is examining why the gene variant confers greater risk in women than in men.
daVId hoNG, MD, was appointed assistant professor of psychiatry and behavioral sciences, effective Nov. 1. He is a child and adolescent psychiatrist who focuses on the evaluation and treatment of neurodevelopmental disorders. He uses neuroimaging and genetic sequencing to establish genotype-phenotype relationships in children with genetic
By Becky Bach
When Bear, the last member of Stanford's colony of narcoleptic dogs, died last year, Emmanuel Mignot, MD, PhD, professor of psychiatry and behavioral sciences, thought he was done keeping dogs with the chronic brain disorder. At least for a while.
But soon after Bear's death, Mignot's phone rang: A dog breeder in the Northeast had a Chihuahua puppy that collapsed to the ground when he got excited. Did Mignot want him?
Bear had left a big hole in his heart, and in the home he shared with his wife, Servane Briand. But he felt he just wasn't ready for a dog. And although he had previously discovered a gene that triggers narcolepsy in some dogs, his research direction had shifted: He was now trying to document the link between the immune system and narcolepsy in humans. Briand, too, was reluctant to adopt a new dog.
But the dog needed a home, and Mignot, who directs the Stanford Center for Sleep Sciences and Medicine, asked himself, who better than an expert on canine narcolepsy to care for the animal?
He flew to Vermont last spring and, once he met the wriggly, black-and-white puppy with a few brown splotches, the decision was made. Now, Watson -named after the character in Sherlock Holmes fiction, the IBM computer personality and the famed geneticist-is in California, reveling in the life of a pampered pooch who just happens to fall asleep when he gets excited.
Although Watson is a bit shy around newcomers, Mignot takes him into the clinic when he treats children with narcolepsy, a growing population that can develop particularly severe symptoms, such as almost constant sleepiness and sudden episodes of muscle paralysis that occur with laughter. Mignot can trigger one of Watson's cataplexies by proffering certain foods, especially Whole Foods roast beef, or by playing with the dog.
Bending down, cooing to Watson in French, Mignot (a native of France) got ready to give the dog a piece of pork. Watson took a big sniff and staggered backwards, struggling to ward off the attack that was paralyzing his musclespushing him toward sleep in just seconds. He recoverd slightly, climbing to his feet and lunging for the food. Sometimes Watson's attacks are quick, other times they occur repetitively, Mignot said. His former narcoleptic dog, Bear, predictably had sleep attacks when he saw any kind of new food, even broccoli, but Watson is a bit more variable, suffering attacks when Mignot arrives home from work or when he spots a favorite toy, Mignot said.
Watson's entertaining performance can calm frightened children and help them understand their condition, Mignot said.
In humans, narcolepsy is caused when the immune system attacks certain neurons in the brain. These neurons produce a peptide called hypocretin that promotes wakefulness and inhibits dreaming. Some dogs have that type of narcolepsy as well, although others have a genetic form that stems from a mutation in the hypocretin peptide receptor gene. Watson is a family pet and has not undergone any kind of genetic testing, so Mignot doesn't know what type of narcolepsy he has.
The Stanford narcoleptic dog colony, started by William Dement, MD, PhD, professor of psychiatry and behavioral sciences, allowed Mignot to discover the genetic basis for canine narcolepsy and enhanced understanding of the human condition, which affects about 1 in 2,000 people. ISM Two Stanford faculty members have been appointed to endowed professorships.
edUaRdo chIchILNISKy, PhD, professor of neurosurgery and of ophthalmology, was appointed the John R. Adler Professor.
Chichilnisky studies how the retina processes visual information and transmits it to the brain. He is also working to develop retinal implants to treat blindness.
The professorship is supported by a gift from Dorothy and Thye King Chan and from an anonymous couple. Dorothy Chan is executive director of the Far East Organization in Singapore, and Thye King Chan is a private equity and property investor.
PeteR KIM, PhD, professor of biochemistry, was appointed the Virginia and D.K. Ludwig Professor of Biochemistry.
Kim studies how viruses enter cells via membrane fusion and is working to develop an HIV vaccine that interferes with the membrane-fusion process. He is also studying proteins that have been deemed "nondruggable" because efforts to target them using drugs have failed.
The 
